SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Mixed quarterly results and an unchanged full-year outlook are fueling debate, with softer bookings and conservative guidance weighing against reported exceptional GTA VI preorders and the games scheduled launch. Bulls see the release as a major growth catalyst, while skeptics warn expectations may already be priced in and the stock could see a sell-the-news reaction.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

A third-quarter earnings beat, stronger-than-expected fourth-quarter guidance and expanded share-repurchase authorization drove a sharp rally, but traders debated whether the results signal a turnaround or mainly beat lowered expectations. Many were bullish on a possible short squeeze, while others focused on flat-to-declining revenue, margin pressure and managements cautious tone, which erased much of the initial after-hours gain.

Avalanche (AVAX) is a cryptocurrency launched in 2020. Avalanche has a current supply of 470,841,831.5537221 with 445,839,831.5537221 in circulation. The last known price of Avalanche is 8.67923054 USD and is up 8.47 over the last 24 hours. It is currently trading on 1134 active market(s) with $528,273,140.94 traded over the last 24 hours. More information can be found at https://avax.network/.

Avalanche

Avalanche is drawing attention after traders discussed the NYSE selecting its blockchain for an upcoming tokenized-securities trading and settlement platform. Reactions are mixed: some view the institutional tokenization news as bullish, while others say AVAXs price response has been modest and fading, and remains sensitive to Bitcoins direction.

Coherent Corp. engages in the development, refinement, manufacturing, and marketing of engineered materials, opto-electronic components and devices, and lasers for use in the industrial, communications, electronics, and instrumentation markets. It operates through the following segments: Networking, Materials, and Lasers. The Networking segment leverages compound semiconductor technology platforms and deep knowledge of end-user applications. The Materials segment markets engineered materials and optoelectronic devices. The Lasers segment serves industrial customers in semiconductor capital equipment, display capital equipment, precision manufacturing, and aerospace and defense, as well as instrumentation customers in life sciences and scientific research. The company was founded by Carl J. Johnson in 1971 and is headquartered in Saxonburg, PA.

Coherent Corp

Coherent is rebounding amid a volatile reaction to strong quarterly results and upbeat guidance, with traders pointing to AI data-center demand for optical components. Bulls see the selloff as overdone and the growth outlook as intact, while bears remain concerned about broader AI-capex uncertainty and further profit-taking.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Deramiocels HOPE-3 cardiac results received an American Heart Association research award, drawing renewed attention ahead of the FDAs November 22 decision. Traders are largely bullish on approval, while debate remains over the awards significance and whether the review will focus on the amended upper-limb indication or the disputed cardiac data.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs quarterly report is driving discussion, with traders weighing an earnings beat against weaker revenue linked to lower Bitcoin prices. Reactions are split: some welcome debt reduction and the buyback authorization, while others discount the results because of unrealized Bitcoin gains and criticize the lack of signed AI/HPC tenant deals.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Discussion centers on Corvus soquelitinib pipeline and the prospect of future clinical data, with bullish traders emphasizing its potential across cancer and inflammatory diseases while skeptics cite delayed readouts, limited evidence, and execution concerns. Posts also highlight reported institutional and insider buying, while buyout and short-squeeze claims remain speculation.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Q3 results disappointed investors, with an unexpected loss, margin pressure, fewer subscribers sequentially and a reduced profit outlook driving the sharp selloff. Traders are split between concerns about near-term profitability and subscriber momentum and optimism that the Lilly partnership and planned peptides launch could support future growth.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell is rebounding with semiconductor stocks as traders point to Nvidia-related uncertainty and possible rotation toward chip rivals, alongside a broader recovery after a steep AI-sector selloff. The bounce has drawn bullish dip-buying, but skepticism remains over the proposed Lumentum deal and lingering concerns about AI infrastructure spending.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Labs Q3 results are driving attention: traders point to record revenue growth, a sharply higher backlog and strong guidance, but the larger-than-expected loss and after-hours pullback have drawn criticism. Debate also centers on Neutrons first launch shifting to no earlier than 2027, with bulls emphasizing its contracted demand and skeptics questioning execution and the time needed to turn backlog into revenue.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Elon Musk Once Said Psychedelics Could Help PTSD  Now FDA Holds Hearing as Optimi Health Advances MDMA Trial

As Elon Musk touts psychedelics for mental health and the FDA holds hearings, Optimi Health (OPTH) supplies commercial MDMA & psilocybin.read more...

Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression

Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression PR Newswire VANCOUVER, BC, June 29, 2026 Optimi's 5mg psilocybin capsules are prescribed in...

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research PR Newswire VANCOUVER, BC, June 16, 2026 Two naturally derived finished drug products, at 1mg and 2mg, give research...

Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial

Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial PR Newswire VANCOUVER, BC, June 10, 2026 The shipment of naturally derived psilocybin, comprising...

Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development

Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development PR Newswire VANCOUVER, BC, June 8, 2026 Recent US executive order named ibogaine compounds among the psychedelic therapies...

Optimi Health (NASDAQ: OPTH) (CSE: OPTI) Highlights Australia Psychedelic Therapy Expansion Following TGA Framework Update

This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising. Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN), a commercial-stage psychedelic pharmaceutical manufacturer, welcomed final recommendations from Australia’s Therapeutic Goods Administration regarding its Authorized Prescriber scheme for psilocybin and MDMA. The updated framework broadens eligible therapy teams, expands treatment settings beyond [&#8230;]

Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia

Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia PR Newswire VANCOUVER, BC, May 29, 2026...

Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting

Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting PR Newswire VANCOUVER, BC, May 20, 2026 Common Shares to Trade on the Nasdaq Capital Market Under...

Optimi Health Corp. functions as an end-to-end GMP manufacturer and supplier of psychedelic substances. It offers formulation, active pharmaceutical ingredients (APIs), and drug product manufacturing from preclinical stages to analysis and commercial distribution and It also offers botanical psilocybin and MDMA. The company was founded on May 27, 2020 and is headquartered in Squamish, Canada.

Optimi Health Corp

Neutral Sentiment

Buying the dip

Selling or trimming

Holding

Waiting for the investigation results to decide

Nvidia ($NVDA) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Stocktwits

) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Current Price	$2.50
Prev Close	$2.34
Open	$2.34
Dividend Yield	0.00%
50-Day Moving Average	$3.94
Beta	0.03
Avg. Volume	28,616.74
PE Ratio	-2.68

52-Week High	$8.84
52-Week Low	$1.90
Market Capitalization	$14.31M
EPS (Annual)	-$0.8297
Price to Book	1.15
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

OPTH Fundamentals